Concord Biotech Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Efficient capital deployment (ROCE 17.1%)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
CONCORDBIO · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FII | 7.00% | 6.49% | 7.11% | 8.10% | 8.33% | 9.35% |
| DII | 8.40% | 8.41% | 10.35% | 9.89% | 9.65% | 9.16% |
| Public | 40.52% | 41.03% | 38.46% | 37.95% | 37.93% | 37.41% |
Corporate Events
Dividend - Rs 7.55 Per Share
Dividend - Rs 10.70 Per Share
Annual General Meeting
Dividend - Rs 8.75 Per Share
Record: 21 Jun 2024
Latest News
All news →Concord Biotech's Limbasi facility clears Brazilian regulator ANVISA inspection
*Concord Biotech's Limbasi API facility has passed the ANVISA inspection by Brazil’s health regulator.* This clearance is a positive step toward potential market access in Brazil. Regulatory approvals like this enhance export prospects and validate manufacturing standards. 📊 *STOCKS:* CONCORDBIO | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #RegulatoryUpdate
Concord Biotech gets FDA-approval for Tofacitinib tablets
*Concord Biotech gets FDA-approval for Tofacitinib tablets* — Concord Biotech has received abbreviated new drug application (ANDA) approval from the US FDA for Tofacitinib Tablets, **5 mg and 10 mg**, paving the way for market entry. The drug is a generic version of Xeljanz, used to treat rheumatoid arthritis and other inflammatory conditions. This approval expands Concord Biotech’s presence in the US generics market. 📊 *STOCKS:* CONCORDBIO | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval
Concord Biotech publishes mandatory newspaper notice
Concord Biotech Limited has issued a copy of its newspaper publication as part of regulatory compliance. The filing does not disclose any financial or operational update. Such notices are routine and typically precede shareholder communications or meetings. No immediate market-moving information was revealed. 📊 *STOCKS:* CONCORDBIO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ConcordBiotech
Concord Biotech shares to remain suspended pending publication
Concord Biotech shares will remain suspended on the NSE pending the newspaper publication as per regulatory requirements. The company has published the notice to comply with listing obligations. No financial impact is indicated at this stage. Traders should monitor for resumption of trading. 📊 *STOCKS:* CONCORDBIO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #suspension
Concord Biotech's Unit-II clears Kenya and Uganda drug inspection
*Concord Biotech's Unit-II clears Kenya and Uganda drug inspection.* The company announced that the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda have completed their inspection of its formulation facility. This regulatory clearance supports export compliance and market access in East Africa. 📊 *STOCKS:* CONCORDBIO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Inspection
Concord Biotech to host analyst and investor meet.
*Concord Biotech to host analyst and investor meet.* The event is aimed at sharing updates with institutional investors and analysts. **No financial figures or strategic announcements** were disclosed in the filing. It’s a routine engagement to maintain investor relations. 📊 *STOCKS:* CONCORDBIO | 🏢 *SECTOR:* Pharma | #LOWIMPACT #investor-meet
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹326 Cr ▲17.3% | ₹278 Cr ▲12.6% | ₹247 Cr ▲21.1% | ₹204 Cr ▼52.6% | ₹430 Cr ▲76.2% | ₹244 Cr ▼21.3% | ₹310 Cr ▲43.5% | ₹216 Cr |
| Op. Profit | ₹118 Cr ▲20.4% | ₹98 Cr ▲11.4% | ₹88 Cr ▲44.3% | ₹61 Cr ▼67.7% | ₹189 Cr ▲92.9% | ₹98 Cr ▼26.9% | ₹134 Cr ▲65.4% | ₹81 Cr |
| OPM | 36.0% ▲2.9% | 35.0% ▼2.8% | 36.0% ▲20.0% | 30.0% ▼31.8% | 44.0% ▲10.0% | 40.0% ▼7.0% | 43.0% ▲13.2% | 38.0% |
| Net Profit | ₹88 Cr ▲37.5% | ₹64 Cr ▲1.6% | ₹63 Cr ▲43.2% | ₹44 Cr ▼68.6% | ₹140 Cr ▲84.2% | ₹76 Cr ▼20.8% | ₹96 Cr ▲60.0% | ₹60 Cr |
| EPS (₹) | 8.49 ▲37.8% | 6.16 ▲1.3% | 6.08 ▲44.4% | 4.21 ▼68.6% | 13.42 ▲84.8% | 7.26 ▼20.7% | 9.15 ▲60.5% | 5.7 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹1.1K Cr ▼12.1% | ₹1.2K Cr ▲18.0% | ₹1.0K Cr ▲19.2% | ₹853 Cr ▲19.6% | ₹713 Cr ▲15.7% | ₹616 Cr ▲20.3% | ₹512 Cr |
| Expenses | ₹687 Cr ▼1.0% | ₹694 Cr ▲18.6% | ₹585 Cr ▲14.9% | ₹509 Cr ▲14.9% | ₹443 Cr ▲53.3% | ₹289 Cr ▼6.2% | ₹308 Cr |
| Op. Profit | ₹368 Cr ▼27.3% | ₹506 Cr ▲17.1% | ₹432 Cr ▲25.6% | ₹344 Cr ▲27.4% | ₹270 Cr ▼17.4% | ₹327 Cr ▲59.5% | ₹205 Cr |
| OPM | 35.0% ▼16.7% | 42.0% ▲0.0% | 42.0% ▲5.0% | 40.0% ▲5.3% | 38.0% ▼28.3% | 53.0% ▲32.5% | 40.0% |
| Other Income | ₹52 Cr ▲18.2% | ₹44 Cr ▲18.9% | ₹37 Cr ▲0.0% | ₹37 Cr ▲60.9% | ₹23 Cr ▲64.3% | ₹14 Cr ▼56.3% | ₹32 Cr |
| Interest | ₹1 Cr ▲0.0% | ₹1 Cr ▼66.7% | ₹3 Cr ▼40.0% | ₹5 Cr ▼16.7% | ₹6 Cr ▲500.0% | ₹1 Cr ▲0.0% | ₹1 Cr |
| Depreciation | ₹74 Cr ▲37.0% | ₹54 Cr ▲0.0% | ₹54 Cr ▲0.0% | ₹54 Cr ▲8.0% | ₹50 Cr ▲78.6% | ₹28 Cr ▲33.3% | ₹21 Cr |
| PBT | ₹345 Cr ▼30.3% | ₹495 Cr ▲19.9% | ₹413 Cr ▲28.3% | ₹322 Cr ▲35.3% | ₹238 Cr ▼24.0% | ₹313 Cr ▲46.3% | ₹214 Cr |
| Tax % | 25.0% ▲0.0% | 25.0% ▲0.0% | 25.0% ▲0.0% | 25.0% ▼3.8% | 26.0% ▲4.0% | 25.0% ▲19.0% | 21.0% |
| Net Profit | ₹259 Cr ▼30.4% | ₹372 Cr ▲20.8% | ₹308 Cr ▲28.3% | ₹240 Cr ▲37.1% | ₹175 Cr ▼25.5% | ₹235 Cr ▲39.1% | ₹169 Cr |
| EPS (₹) | 24.94 ▼29.8% | 35.52 ▲20.6% | 29.45 ▲28.3% | 22.95 ▼87.5% | 183.93 ▼25.7% | 247.44 ▲39.2% | 177.81 |
| Div Payout | 30.0% ▲20.0% | 25.0% ▼16.7% | 30.0% ▲0.0% | 30.0% ▲900.0% | 3.0% | 0.0% ▼100.0% | 22.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Liabilities | |||||||
| Equity Capital | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr ▲0.0% | ₹10 Cr |
| Reserves | ₹2.0K Cr ▲11.4% | ₹1.8K Cr ▲18.9% | ₹1.5K Cr ▲18.4% | ₹1.3K Cr ▲17.0% | ₹1.1K Cr ▲10.5% | ₹990 Cr ▲30.1% | ₹761 Cr |
| Borrowings | ₹2 Cr ▼33.3% | ₹3 Cr ▼70.0% | ₹10 Cr ▼68.8% | ₹32 Cr ▼48.4% | ₹62 Cr ▼27.9% | ₹86 Cr ▲65.4% | ₹52 Cr |
| Other Liabilities | ₹212 Cr ▼3.2% | ₹219 Cr ▲33.5% | ₹164 Cr ▼14.6% | ₹192 Cr ▲30.6% | ₹147 Cr ▲51.5% | ₹97 Cr ▼17.8% | ₹118 Cr |
| Total Liabilities | ₹2.2K Cr ▲9.7% | ₹2.0K Cr ▲19.6% | ₹1.7K Cr ▲12.4% | ₹1.5K Cr ▲15.3% | ₹1.3K Cr ▲11.0% | ₹1.2K Cr ▲25.7% | ₹941 Cr |
| Assets | |||||||
| Fixed Assets | ₹789 Cr ▼0.8% | ₹795 Cr ▲38.3% | ₹575 Cr ▼3.0% | ₹593 Cr ▲3.5% | ₹573 Cr ▲4.9% | ₹546 Cr ▲127.5% | ₹240 Cr |
| CWIP | ₹79 Cr ▲54.9% | ₹51 Cr ▼75.8% | ₹211 Cr ▲22.0% | ₹173 Cr ▲133.8% | ₹74 Cr ▲311.1% | ₹18 Cr ▼87.2% | ₹141 Cr |
| Investments | ₹491 Cr ▲46.6% | ₹335 Cr ▲36.2% | ₹246 Cr ▲79.6% | ₹137 Cr ▲85.1% | ₹74 Cr ▼47.5% | ₹141 Cr ▼29.1% | ₹199 Cr |
| Other Assets | ₹873 Cr ▲2.2% | ₹854 Cr ▲27.8% | ₹668 Cr ▲9.3% | ₹611 Cr ▲3.2% | ₹592 Cr ▲24.1% | ₹477 Cr ▲32.1% | ₹361 Cr |
| Total Assets | ₹2.2K Cr ▲9.7% | ₹2.0K Cr ▲19.6% | ₹1.7K Cr ▲12.4% | ₹1.5K Cr ▲15.3% | ₹1.3K Cr ▲11.0% | ₹1.2K Cr ▲25.7% | ₹941 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Operating CF | ₹267 Cr ▲9.0% | ₹245 Cr ▼7.5% | ₹265 Cr ▲7.7% | ₹246 Cr ▲18.8% | ₹207 Cr ▲24.0% | ₹167 Cr ▲7.7% | ₹155 Cr |
| Investing CF | ₹-143 Cr ▲10.6% | ₹-160 Cr ▼3.2% | ₹-155 Cr ▲1.9% | ₹-158 Cr ▼41.1% | ₹-112 Cr ▲42.6% | ₹-195 Cr ▼71.1% | ₹-114 Cr |
| Financing CF | ₹-113 Cr ▼14.1% | ₹-99 Cr ▲0.0% | ₹-99 Cr ▼16.5% | ₹-85 Cr ▲15.0% | ₹-100 Cr ▼422.6% | ₹31 Cr ▲172.1% | ₹-43 Cr |
| Net Cash Flow | ₹11 Cr ▲178.6% | ₹-14 Cr ▼216.7% | ₹12 Cr ▲300.0% | ₹3 Cr ▲175.0% | ₹-4 Cr ▼233.3% | ₹3 Cr ▲400.0% | ₹-1 Cr |
| Free Cash Flow | ₹172 Cr ▲28.4% | ₹134 Cr ▼25.6% | ₹180 Cr ▲78.2% | ₹101 Cr ▲94.2% | ₹52 Cr ▲236.8% | ₹-38 Cr ▼3700.0% | ₹-1 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 159d ▲0.0% | 159d ▲27.2% | 125d ▲6.8% | 117d ▼1.7% | 119d ▲13.3% | 105d ▼19.8% | 131d |
| Inventory Days | 485d ▲69.6% | 286d ▼13.6% | 331d ▼23.0% | 430d ▼0.9% | 434d ▼13.7% | 503d ▲61.2% | 312d |
| Days Payable | 151d ▲11.9% | 135d ▼10.0% | 150d ▼21.1% | 190d ▲2.7% | 185d ▲21.7% | 152d ▼24.4% | 201d |
| Cash Conv. Cycle | 493d ▲59.0% | 310d ▲1.3% | 306d ▼14.3% | 357d ▼3.0% | 368d ▼19.3% | 456d ▲88.4% | 242d |
| Working Capital Days | 230d ▲19.2% | 193d ▲16.3% | 166d ▲9.2% | 152d ▼5.6% | 161d ▼9.0% | 177d ▲11.3% | 159d |
| ROCE | 17.0% ▼39.3% | 28.0% ▲0.0% | 28.0% ▲7.7% | 26.0% ▲23.8% | 21.0% ▼34.4% | 32.0% | — |
Source: Screener.in · Lower days = better efficiency
About Concord Biotech Limited
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
Healthcare · Pharmaceuticals & Biotechnology